Epstein Secrets

& ENTERTAINMENT 1st Circ. Rejects Priest's $100M Bloomberg Defamation Suit `',Law360 Pro Say Podcast Liste

wns, numbing agents, X-ray accessories and other products, the parties announced on Thursday. Read full article » CONTRACTS DOJ Says It Can Prove Novartis Dinners Were Kickbacks The U.S. Department of Justice shot back against Novartis Pharmaceuticals Corp.'s claims that extensive discovery hasn't tur

BTI Consulting Group Inc. Bank of America Corporation Barclays PLC Baring Private Equity Asia Ltd. Benco Dental Supply Co. Inc. BlackBerry Ltd. Bloomberg Bombardier Inc. CenterPoint Energy Inc. Citigroup Inc. Competitive Enterprise Institute Devon Energy Corp. Enlink Midstream Partners LP Exterro

led in Feb (unchanged from Jan vs estimate 40.6%) Marks & Spencer gains the most in six months as sales fall less than estimated (trading 45.47%) Novartis asks EU regulators to approve the Prexige pain pill that was pulled off the market 4 years ago German factory orders climb almost 5x faster than es

er Newspaper Articles & Stories Barron's positive: Cloud Peak Energy (CLD) Banks may avoid threatened financial penalties for faulty foreclosures - Bloomberg NFLX and Lionsgate unite for exclusive syndication arrangement for Mad Men - Bloomberg Bloomberg Berlusconi sex, abuse-of-power trial is postpone

ivity Yesterday: EFA (50.31 -0.1%)- Bullish customer bought 75,418 Dec 53 calls for $1.52 ($11.46mm in premium). Top 5 components are Nestle, HSBC, Novartis and BP. AIG (31.72 +0.5%) - A customer bot 9,352 $32c that expire friday for .60. Earnings 8/2. GLD ($157.43 -0.1%)- A customer expecting to see a

plans to give the ESM a banking license to give it access to unlimited ECB funding are gaining support (although Germany still opposes). Headline on Bloomberg saying Merkel adviser Bofinger advocates ECB buying of government bonds getting some attention but note this is not a new opinion from Bofinger. So

ar, LFL's strong (trading -0.16%) • Astrazeneca eps slightly lower than estimates, maintains guidance, pipeline update positive (trading +4.0%) • Novartis O1 core eps and net meet estimates, fx impact, sales miss, guidance reiterated (trading -1.1%) • Novozymes Q1 beats estimates, now sees 2014 net pr

els of the after-hours strength in the US following earnings beats from the likes of AAPL, FB, CTXS, TXN, etc. On the M&A front, Alstom +13% on the Bloomberg story that GE is interested in buying them for $13B although Alstom says they are unaware of any potential bid. Other than that it is the heaviest e

e reporting inline with recent pre-announcement and guiding touch lower). Healthcare +1.28% & Food/Beverages +0.72% also outperforming in Europe as Novartis +3.8% & Unilever +2.4% break-out after reporting solid numbers. Volumes heavy across the region with Estoxx600 turnover currently —130% of 3-month a

fense and Rep. Tom Cole says they are prepared to let them trigger even if the Dems don't agree to restructure them to fall less heavily on Defense (Bloomberg). Tech +0.95% strong in Europe, helped by solid numbers from GOOG, IBM, CREE after the close in the US (note XLK in US has underperformed only +2.1

bserver), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Sci

es for the foreseeable future. 29 eValuatePharma 3° Burrill Biotech 2012 Report " New Leaf Analysis of public company financial data as provided by Bloomberg » Battelle R&D Magazine Annual Global R&D Funding Forecast 37 CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024048 The Fund Managers expect th

Marley Natural, Irisa, Goodship, Grail, and Dutchy. TLRY has been active on the M&A front, with previously announced acquisitions / partnerships with Novartis, Authentic Brands and AB-Inbev, among others. Most recently, the company announced a C$419 mm acquisition of Manitoba Harvest, the global leader in h

2017A 2018E 2019E 2020E Source: Company Reports, Bloomberg COWEN.COM HOUSE_OVERSIGHT_024876 COWEN COLLABO